ProofPilot and Inspire announced a strategic partnership on April 1, 2025, aimed at dramatically expanding patient recruitment for clinical trials. The collaboration brings together ProofPilot's end-to-end Clinical Experience Platform (CXP) with Inspire's extensive online health community to address one of the pharmaceutical industry's most persistent challenges: finding and engaging suitable participants for clinical research.
The partnership integrates Inspire into ProofPilot's Patient Recruitment Network, enabling patients and caregivers from Inspire's global community to more easily discover and participate in relevant clinical trials. This collaboration comes at a critical time when patient recruitment continues to be a significant bottleneck in the clinical trial process.
Leveraging Patient Communities for Clinical Research
Inspire's community encompasses over 10 million unique annual visitors across more than 3,000 disease states, representing a vast and diverse patient population. By connecting this community with ProofPilot's platform, the partnership aims to create a more efficient pathway for patients seeking clinical trial opportunities.
Brett Kleger, CEO of Inspire, emphasized the alignment of the partnership with their community's interests: "The Inspire community is filled with individuals eager to participate in the advancement and transformation of clinical research. By partnering with a tech company like ProofPilot, we can seamlessly connect patients to meaningful clinical trial opportunities, allowing us to focus on what we do best – holistic, year-round engagement of our community."
The collaboration is designed to enhance Inspire's impact in two key ways: expanding opportunities to connect community members with life-advancing clinical trials and providing an end-to-end digital experience to optimize participation.
Transforming the Clinical Trial Experience
ProofPilot's platform is specifically designed to optimize both recruitment and ongoing engagement of trial participants. The company's CoPilot platform supports various research types, making clinical trials more accessible and patient-friendly.
"At ProofPilot, we're committed to transforming the clinical trial experience for both sponsors and patients," said Chris Venezia, CEO of ProofPilot. "Our partnership with Inspire allows us to leverage their extensive patient community to accelerate recruitment and connect patients with life-changing research opportunities. We're excited to work with Inspire to break down barriers to study participation."
Addressing Industry-Wide Challenges
Patient recruitment has long been a significant hurdle in clinical research, with many trials facing delays or even cancellation due to insufficient enrollment. This partnership represents a strategic approach to addressing this challenge by connecting motivated patients with appropriate research opportunities.
The collaboration also reflects a growing trend in the industry toward patient-centered trial design and recruitment strategies. By creating more direct pathways between patient communities and clinical trials, the partnership aims to reduce the time and resources typically required for recruitment while improving the overall patient experience.
Complementary Expertise
Founded in 2005, Inspire has established itself as a vital connection point between life sciences organizations and patient communities. Beyond recruitment, Inspire offers capabilities including real-world evidence generation, market research, and targeted advertising solutions for health-focused audiences.
ProofPilot brings over a decade of experience in clinical trial management, with a focus on digital innovation to streamline the research process. Their comprehensive platform supports the design, management, and execution of clinical trials across various therapeutic areas.
Together, the companies aim to create a more efficient ecosystem for clinical research that benefits patients seeking treatment options, researchers looking for participants, and ultimately, the advancement of medical science through more efficient clinical trials.
